FOLFOX in Neuroendocrine Tumors

#1387

Introduction: Favorable toxicity profile and significant antitumor activity of FU-oxaliplatin in several malignancies led us to evaluate FOLFOX in advanced neuroendocrine carcinomas (NETs).

Aim(s): Evaluate the efficacy, Progression-free (PFS) and Overall survival (OS) respectively

Materials and methods: We performed a retrospective study in 31 patients with metastatic digestive and lung well-differentiated G1-G2 NETs with progressive disease treated with FOLFOX regimen chemotherapy. Were registered improvement of clinical symptoms and radiological response.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Faure M

Authors: Faure M, Raoul J, Autret A, Mineur L, Boustany R,

Keywords: Neuroendocrine tumors, folfox, clinical improvement, break in treatment, PFS, OS,